Related Experiment Video

Updated: Feb 19, 2026

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

15.5K

Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and

Jennifer M Lehmann1, Karina Claus1, Christian Jansen1

  • 1Department of Internal Medicine I, University Clinic Bonn, Bonn, Germany.

Liver International : Official Journal of the International Association for the Study of the Liver
|November 7, 2017
PubMed

Insights

In severe portal hypertension, higher circulating CXCL10 levels correlate with decompensation and mortality. A decrease in CXCL10 after transjugular intrahepatic portosystemic shunt (TIPS) indicates better survival.

Area of Science:

  • Hepatology
  • Immunology
  • Vascular Biology

Background:

  • Chemokine (C-X-C motif) ligand 10 (CXCL10) role in severe portal hypertension is unknown.
  • CXCR% ligands are implicated in hepatic injury, inflammation, and fibrosis.
  • CXCL9 and CXCL11 are linked to survival in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS).

Purpose of the Study:

  • Investigate the role of CXCL10 in severe portal hypertension.
  • Determine if CXCL10 levels predict outcomes in patients receiving TIPS.
  • Assess the prognostic value of CXCL10 level changes post-TIPS.

Main Methods:

  • Analyzed 89 cirrhotic patients.
  • Measured CXCL10 protein levels in portal and hepatic blood pre- and post-TIPS.
  • Assessed CXCL10 and IL-8 levels in multiple blood compartments.
  • Determined hepatic CXCL10-mRNA via real-time PCR.

Main Results:

  • Circulating CXCL10 levels were higher in portal than hepatic veins, suggesting extrahepatic origin.
  • Elevated CXCL10 correlated with ascites, higher Child scores, acute decompensation, acute-on-chronic liver failure (ACLF), and mortality.
  • Decreased CXCL10 post-TIPS was associated with improved survival.

Conclusions:

  • Circulating CXCL10 reflects systemic inflammation in severe portal hypertension.
  • CXCL10 predicts survival and complications in TIPS patients.
  • A post-TIPS decrease in CXCL10 is a favorable prognostic indicator.
Abstract

Keywords:
ACLFchemokinescirrhosisportal hypertensiontransjugular intrahepatic portosystemic shunt

More Related Videos

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

54.8K
Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice11:44

Long Term Intravital Multiphoton Microscopy Imaging of Immune Cells in Healthy and Diseased Liver Using CXCR6.Gfp Reporter Mice

Published on: March 24, 2015

12.6K

Related Concept Videos

Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.5K
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
767
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
259
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
393